Immatics deepens relationship with pharma major in up to $4.2 billion deal

2 June 2022
immatics-logo-big

Immatics Biotechnologies (Nasdaq; IMTX) saw its American-traded shares rise just a modest 3.2% to $7.79 this morning, despite signing a multi-billion-dollar deal, albeit heavily back-loaded.

The German drug developer and Bristol Myers Squibb (NYSE: BMY) have expanded their strategic alliance to pursue the development of multiple allogenic cell therapy programs and add another program to their existing 2019 collaboration agreement.

As part of the new agreement, the companies will combine Immatics’ proprietary gamma delta T cell-derived, allogeneic Adoptive Cell Therapy (ACT) platform, called ACTallo, with BMS’ next-generation technologies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology